이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Alvotech 과거 수익 실적

과거 기준 확인 0/6

Alvotech의 수입은 연평균 -37.6%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 15.5%의 비율로 증가했습니다. 매출은 연평균 14.3%의 비율로 증가해 왔습니다.

주요 정보

-37.6%

수익 성장률

102.7%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	14.3%
자기자본 수익률	n/a
순이익	-432.1%
다음 실적 업데이트	28 Aug 2024

최근 과거 실적 업데이트

Recent updates

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Sep 03

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

May 05

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Nov 23

Alvotech starts pharmacokinetic study for its biosimilar to Amgen's bone disease drugs

Jul 20

수익 및 비용 분석

Alvotech 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:ALVO 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	114	-494	67	191
31 Dec 23	93	-552	74	192
30 Sep 23	64	-596	120	179
30 Jun 23	65	-416	110	172
31 Mar 23	100	-713	101	182
31 Dec 22	85	-514	76	181
30 Sep 22	96	61	51	171
30 Jun 22	78	-12	34	187
31 Mar 22	39	-42	66	190
31 Dec 21	40	-102	68	191
31 Dec 20	69	-170	59	146
31 Dec 19	83	-210	49	96

양질의 수익: ALVO 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ALVO 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: ALVO 은(는) 수익성이 없으며 지난 5년 동안 연간 37.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 ALVO 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ALVO 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: ALVO 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Alvotech 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Recent updates

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Consensus revenue estimates increase by 45%

Consensus revenue estimates decrease by 41%, EPS upgraded

New major risk - Financial position

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Price target decreased by 25% to US$8.10

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Consensus revenue estimates fall by 26%

Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

New minor risk - Share price stability

Consensus revenue estimates decrease by 15%, EPS upgraded

Forecast breakeven date moved forward to 2024

Price target decreased by 8.8% to US$12.40

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump

Alvotech to Report Q1, 2023 Results on May 18, 2023

Consensus revenue estimates increase by 10%

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Consensus EPS estimates fall by 12%

Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Less than half of directors are independent